Quotazioni in diretta

NBY NovaBay Pharmaceuticals Inc New

0,1213

0,0013 (1,08%)

18 Mag 2024 - Chiuso

Dati in Delay di 15 minuti

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Grafico Azioni NovaBay Pharmaceuticals (AMEX:NBY)
Storico
Da Apr 2024 a Mag 2024

Clicca qui per i Grafici di NovaBay Pharmaceuticals

Grafico Azioni NovaBay Pharmaceuticals (AMEX:NBY)
Storico
Da Mag 2023 a Mag 2024

Clicca qui per i Grafici di NovaBay Pharmaceuticals

Notizie NovaBay Pharmaceuticals Inc New - NBY

NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
Lunedì 13 Maggio 2024 (5 giorni fa) • Business Wire

NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
Giovedì 9 Maggio 2024 (1 settimana fa) • Business Wire

NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
Martedì 7 Maggio 2024 (2 settimane fa) • Business Wire

NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
Venerdì 3 Maggio 2024 (2 settimane fa) • Business Wire

NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
Lunedì 22 Aprile 2024 (4 settimane fa) • Business Wire

NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
Sabatp 20 Aprile 2024 (4 settimane fa) • Business Wire

NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
Mercoledì 17 Aprile 2024 (1 mese fa) • Business Wire

NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
Martedì 26 Marzo 2024 (2 mesi fa) • Business Wire

NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
Lunedì 25 Marzo 2024 (2 mesi fa) • Business Wire

NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
Giovedì 14 Marzo 2024 (2 mesi fa) • Business Wire

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Mercoledì 14 Febbraio 2024 (3 mesi fa) • Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Martedì 6 Febbraio 2024 (3 mesi fa) • Edgar (US Regulatory)

Più NovaBay Pharmaceuticals Inc New Articoli Notizie

Crown Place Vct

Societe Generale Effekten

Societe Generale Effekten

BNP PARIBAS ISSUANCE

BNP Paribas Issuance

X India Govi Bo

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea